

Tolérance centrale

Sélection positive et négative des répertoires lymphocytaires

Adrien Six (adrien.six@upmc.fr)
Université Pierre et Marie Curie

IF-IIIb
février 2010

IF2010 BMC423 IF-IIIb

1


Sélection positive et négative des répertoires lymphocytaires

1. Introduction
2. Sélection des répertoires B
3. Sélection des répertoires T
4. Conclusion

IF2010 BMC423 IF-IIIb

2

Les lymphocytes B et T




→ caractérisés par leur récepteur spécifique d'antigène

IF2010 BMC423 IF-IIIb

5

Diversité des chaînes Ig et TCR

- La diversité des chaînes d'Ig et de TCR est le produit de :
 - Combinatoire des segments V(D)J
 - Appariement IgH/L, TCR α / β or TCR γ / δ
 - Ajout/élimination aléatoire de nucléotides à la jonction des segments géniques (CDR3)



IF2010 BMC423 IF-IIIb

6

Estimation de la diversité (2)


Mechanism of diversity	IMMUNOGLOBULINS		αβ T-CELL RECEPTOR		γδ T-CELL RECEPTOR	
	H Chain	κ Chain	α Chain	β Chain	γ Chain	δ Chain
ESTIMATED NUMBER OF FUNCTIONAL GENE SEGMENTS*						
V	101	85	79	21	7	6
D	13	0	0	2	0	2
J	4	4	38	11	3	2
POSSIBLE NUMBER OF COMBINATIONS†						
Combinatorial V-J	$101 \times 13 \times 4$	85×4	79×38	$21 \times 2 \times 11$	7×3	$6 \times 2 \times 2$
and V-D-J joining	5.3×10^3	3.4×10^2	3.0×10^3	4.6×10^2	21	24
Alternative joining of D gene segments	-	-	-	(some)	-	(often)
Junctional flexibility	+	+	+	+	+	+
N-region nucleotide addition‡	+	~10 ¹²	+	~10 ¹⁵	+	~10 ¹⁸
P-region nucleotide addition	+	+	+	+	+	+
Somatic mutation	+	+	-	-	-	-
Combinatorial association of chains	+	+	+	+	+	+

*Immunoglobulin data from Table 5-3; TCR data from Baum et al., 2004, *Nucleic Acids Research* 32:D51.
 †A plus sign (+) indicates mechanism makes a significant contribution to diversity but to an unknown extent.
 ‡A minus sign (-) indicates mechanism does not operate.
 ††See Figure 9-8d for theoretical number of combinations generated by N-region addition.

IF2010 BMC
 © 2007 W. H. Freeman and Company

7

Parallèle différenciations B et T




© 1998 Current Opinion in Immunology

IF2010 BMC423 IF-IIIb

D'après Fitzsimmons et Hagman (1996) *Curr. Op. Immunol.* 8:166.

8

Mise en place des répertoires



IF2010 BMC423 IF-IIIb

9


Sélection positive et négative des répertoires lymphocytaires

1. Introduction
2. Sélection des répertoires B
3. Sélection des répertoires T
4. Conclusion

IF2010 BMC423 IF-IIIb

10


Sélection des lymphocytes B (1)



IF2010 BMC423 IF-IIIb

© 2000 John Wiley & Sons, Inc. 11


Sélection des lymphocytes B (2)



IF2010 BMC423 IF-IIIb

12


Délétion clonale (1)

Figure 11-15a
Kuby IMMUNOLOGY Sixth Edition
© 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

13

Délétion clonale (2)

Figure 11-15b
Kuby IMMUNOLOGY Sixth Edition
© 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

14

Anergie (1)




Figure 11-14a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2010 BMC423 IF-IIIb

15

Anergie (2)





Figure 11-14b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2010 BMC423 IF-IIIb

16

Sélection des lymphocytes B (3)



IF2010 BMC423 IF-IIIb

17

Sélection des lymphocytes B (4)


Attribute	Conventional B cells (B-2 B cells)	B-1 B cells
Major sites	Secondary lymphoid organs	Peritoneal and pleural cavities
Source of new B cells	From precursors in bone marrow	Self-renewing (division of existing B-1 cells)
V-region diversity	Highly diverse	Restricted diversity
Somatic hypermutation	Yes	No
Requirements for T-cell help	Yes	No
Isotypes produced	High levels of IgG	High levels of IgM
Response to carbohydrate antigens	Possibly	Definitely
Response to protein antigens	Definitely	Possibly
Memory	Yes	Very little or none
Surface IgD on mature B cells	Present on naive B cells	Little or none

Figure 11-5
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2010 BMC423 IF-IIIb

23


Sélection des lymphocytes B (5)



IF2010 BMC423 IF-IIIb

24


Hypermutations en absence d'antigène



IF2010 BMC423 IF-IIIb

Weller et al. (2008) *J. Exp. Med.* 205:1331. 31

Hypermutations en absence d'antigène



IF2010 BMC423 IF-IIIb

32

Compétition antigénique

TABLE 11-7 Antigenic competition between sheep and horse RBCs			
IMMUNIZING ANTIGEN		HEMOLYTIC PLAQUE ASSAY (DAY 8)	
Ag1 (day 0)	Ag2 (day 3)	Test Ag	PFC / 10 ⁶ spleen cells
None	HRBC	HRBC	205
SRBC	HRBC	HRBC	13
None	SRBC	SRBC	626
HRBC	SRBC	SRBC	78

Table 11-7
Ruby's Immunology, Sixth Edition
 © 2007 by W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

33

Dominance clonale: idiotype T15 (1)

Anticorps inhibiteurs	Nombre de PFC anti-PC/rate
-	120 000
S1 60	115 000
S1 04	117 000
2E8	800
F6	950

-S160, S104, 2E8 et F6 sont quatre anticorps monoclonaux anti-T15, une immunoglobuline IgA, κ anti-phosphorylcholine.

-S160 est dirigé contre un épitope de IgA; κ ; S104 est spécifique de IgA, κ ; 2E8 et F6 sont des anticorps anti-idiotypiques.

-Les quatre anticorps ont été utilisés pour tenter d'inhiber des plages d'hémolyses locales (PFC) obtenues en mélangeant *in vitro* des cellules de souris BALB/c anti-PC, de la PC couplée à des globules rouges de mouton et du complément.

IF2010 BMC423 IF-IIIb

34

Dominance clonale: idiotype T15 (2)

TABLE 1
Number of PC-Specific Foci and Percentages of T15⁺ Foci as a Function of Development

Age of donor mice in days ^a	Number of donor mice ^b	Total number of cells analyzed	Number of PC ⁺ foci	Frequency (in 10 ⁶ spleen cells) ^c	Number of T15 ⁺ foci	%T15 ⁺
2	58	2×10 ⁶	0	0	0	0
3	52	2×10 ⁶	0	0	0	0
4	31	2×10 ⁶	1	0.125	0	0
6	17	2×10 ⁶	7	0.875	2	28.5
7	13	3×10 ⁶	15	1.2	6	40.0
8	7	10 ⁶	7	1.7	4	57.1
9	5	10 ⁶	13	3.2	9	69.2
10	6	1.8×10 ⁶	30	4.1	24	80.0
12	4	1.5×10 ⁶	28	4.6	25	89.2
21	1	1.2×10 ⁶	18	3.7	16	88.8
42-46	1	2×10 ⁶	69	8.6	63	91.3

^aThe day of birth was counted as day 1. Thus, an age of 2 indicates 1 day after birth, age of 3 indicates 2 days after birth, etc.

^bSpleen cells from mice born within 12 hr of each other were pooled. Results from experiments performed on different days were pooled for the table.

^cCalculated as per Sigal et al. (1977).

Vakil, Briles & Kearney (1991) *Dev. Immunol* 1:203.

IF2010 BMC423 IF-IIIb

35

Dominance clonale: idiotype T15 (3)

Injection néonatale de R36A *S. pneumoniae* + challenge R36A à 7 semaines
→ Dosage Ac anti-PC




TABLE 3

Treatment of serum donor		Alive/dead postchallenge	
neonatal	adult	3 days	10 days
None	R36A	7/0	5/2
R36A	R36A	0/4 ^a	0/4 ^a
None	None	0/7 ^a	0/7 ^a
No serum		0/7 ^a	0/7 ^a

^aDifferent from none/R36A at $p < 0.01$.

^bDifferent from none/R36A at $p < 0.001$.

^cDifferent from none/R36A at $p < 0.06$.

Challenge léthal *S. pneumoniae*
→ Pouvoir protecteur du sérum de souris préalablement exposées?

Vakil, Briles & Kearney (1991) *Dev. Immunol* 1:203.

IF2010 BMC423 IF-IIIb


36

Sélection positive et négative des répertoires lymphocytaires

1. Introduction
2. Sélection des répertoires B
3. Sélection des répertoires T
4. Conclusion

IF2010 BMC423 IF-IIIb

37




Sélections positive et négative (1)

- Sélection positive: le TCR doit avoir une certaine réactivité avec une molécule du CMH du soi
- L'expression du co-récepteur CD4/CD8 suit la restriction pour le CMH
→ CD4/classe II et CD8/classe I
- Sélection négative: les cellules T autoréactives (reconnaissant CMH + peptide du soi) sont éliminées

IF2010 BMC423 IF-IIIb

57


Sélections positive et négative (2)




→ Éducation thymique

IF2010 BMC423 IF-IIIb

58



Rôle de l'épithélium thymique dans la sélection positive (1)



IF2010 BMC423 IF-IIIb

60

Rôle de l'épithélium thymique dans la sélection positive (2)


Thymectomize <i>b</i> × <i>k</i> mice	Graft with thymus of haplotype	Irradiate and reconstitute with <i>b</i> × <i>k</i> bone marrow	Prime with KLH	Proliferative response of primed T-cells to KLH on antigen-presenting cells of haplotype	
				H-2 ^b	H-2 ^k
	<i>b</i> × <i>k</i>	→	→	++	++
	<i>b</i>	→	→	++	-
	dGuo-treated <i>b</i>	→	→	++	-
	<i>k</i>	→	→	-	++
	dGuo-treated <i>k</i>	→	→	-	++

From: Rott's Essential Immunology Eleventh Edition

IF2010 BMC423 IF-IIIb

61


Sélection positive & CMH (1)



IF2010 BMC423 IF-IIIb

64

Sélection positive & CMH (4)

Fonds C57BL/6 I-E (I-E α), I-A⁺
IF2010 BMC423 IF-IIIb

Brocker, Riedinger & Karjalainen (1997) J. Exp. Med. 185:541. 65

Sélection positive & CMH (3)

TABLE 10-1

Effect of class I or II MHC deficiency on thymocyte populations*

Cell type	Control mice	KNOCKOUT MICE	
		Class I deficient	Class II deficient
CD4 ⁺ CD8 ⁻	+	+	+
CD4 ⁺ CD8 ⁺	+	+	+
CD4 ⁺	+	+	-
CD8 ⁺	+	-	+

*Plus sign indicates normal distribution of indicated cell types in thymus. Minus sign indicates absence of cell type.

Table 10-1
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2010 BMC423 IF-IIIb

66

Sélection positive & CMH (4)





Figure 10-7
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb


67

Sélection positive & CMH (2)



IF2010 BMC423 IF-IIIb


68



IF2010 BMC423 IF-IIIb

Godfrey and Zlotnik (1993) *Immunol.Today* 14:457. 70

Induction de la tolérance



→ Rôle des peptides du soi → Délétion clonale

IF2010 BMC423 IF-IIIb

71



IF2010 BMC423 IF-IIIb

72

Délétion clonale et superantigènes (1)




Figure 10-16
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

73

Délétion clonale et superantigènes (2)

TABLE 10-3 Exogenous superantigens and their V _β specificity			
Superantigen	Disease ^a	V _β SPECIFICITY	
		Mouse	Human
Staphylococcal enterotoxins			
SEA	Food poisoning	1, 3, 10, 11, 12, 17	nd
SEB	Food poisoning	3, 8.1, 8.2, 8.3	3, 12, 14, 15, 17, 20
SEC1	Food poisoning	7, 8.2, 8.3, 11	12
SEC2	Food poisoning	8.2, 10	12, 13, 14, 15, 17, 20
SEC3	Food poisoning	7, 8.2	5, 12
SED	Food poisoning	3, 7, 8.3, 11, 17	5, 12
SEE	Food poisoning	11, 15, 17	5.1, 6.1-6.3, 8, 18
Toxic shock syndrome toxin (TSST1)	Toxic shock syndrome	15, 16	2
Exfoliative dermatitis toxin (ExFT)	Scalded skin syndrome	10, 11, 15	2
Mycoplasma arthritis supernatant (MAS)	Arthritis, shock	6, 8.1-8.3	nd
Streptococcal pyrogenic exotoxins (SPE-A, B, C, D)	Rheumatic fever, shock	nd	nd

^aDisease results from infection by bacteria that produce the indicated superantigens.

^aDisease results from infection by bacteria that produce the indicated superantigens.

Table 10-3
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

74

Délétion clonale et superantigènes (3)

TABLE II
Vβ Specificity of MMTV Encoded Super-antigens

Mtv	Chromosome	Super-antigen	Vβ specificity	References
1	7	Mls-2	3	41
2	18		14	44
3	11		3, 17a	89, 92
6	16	Etc-2/Mls-3	3, 5.1, 5.2	35, 40, 41
7	1	Mls-1	6, 7, 8.1, 9	41
8	6	Dvb11-1	5.1, 5.2, 11, 17a	39, 40
9	12	Etc-1/Dvb11-2	5.1, 5.2, 11, 12, 17a	33, 34, 38, 39, 40, 55
11	14	Dvb11-3	11	39
13	4	Mls-2	3	41
?	?		16*	26, 27
?	?		19a*	—
?	?		20	29
C3H-exo			14, 15	42, 43
BALB/c tumor			2	90


*Super-antigen implicated but not yet demonstrated.

†R. J. Hodes, unpublished.

IF2010 BMC423 IF-IIIb

Woodland & Blackman (1992) *Int. Rev. Immunol.* 8:311. 75


Délétion clonale et superantigènes (4)





IF2010 BMC423 IF-IIIb

76

Délétion clonale et superantigènes (5)



© Current Biology Ltd/Garland Publishing



© Current Biology Ltd/Garland Publishing

IF2010 BMC423 IF-IIIb

77

Délétion clonale et superantigènes (6)


Table 1. Strain distribution of some Mtv proviruses (adapted from Annu. Rev. Cell Biol. 1993 9:101-28)

MTV	1	3	6	7	8	9	11	13	14	17	23	29	30	31†
Chromosome	7	11	16	1	6	12	14	4	4	4	6	6	12	Y
cM from centromere	31	72	31	73	31	40	8	47	10	20	32	2034	2	
Vb Specificity (Vb allele if not h)	3, 177	3, 5, 177	3, 5, 177	6, 7, 8.1, 11, 12	5, 11, 12	5, 11, 12	11, 12	3, 177	NE	NE	7	16	NE	?
Strains	H2	IE												
A/J	a	k	-	+	+	-	+	-	+	-	+	-	+	+
AKR/J	k	k	-	-	+	+	+	-	-	+	+	-	+	+
BALB/cByJ	d	d	-	-	+	+	+	-	-	-	-	-	-	-
B10.BR	k	k	-	-	-	+	+	+	-	+	-	-	+	-
C3H/HeJ	k	k	+	+	+	+	+	+	+	+	+	+	+	+
C57BL/6J	b	-	-	-	-	+	+	-	-	-	+	-	+	-
C57BR/cdJ(a)	k	k	-	-	-	+	+	+	-	+	-	+	+	?
C57L/J (a)	b	-	-	-	-	+	+	+	-	-	+	-	+	?
C58/J	k	k	-	+	+	-	-	-	-	+	-	-	+	-
CBA/CaJ	k	k	-	-	-	+	+	-	+	+	-	-	-	-
CBA/J	k	k	-	-	+	+	+	-	+	+	-	-	-	-

IF2010 BMC423 IF-IIIb

Scherer et al. (1993) *Annu. Rev. Cell Biol.* 9:101. 78


Sélection négative & superantigène (7)




IF2010 BMC423 IF-IIIb

Baey & Thomas-Vaslin (2009) non publié. 79

Sélection négative & superantigène (8)


Fonds C57BL/6 I-E (I-E α^-), I-A⁺
IF2010 BMC423 IF-IIIbBrocker, Riedinger & Karjalainen (1997) *J. Exp. Med.* 185:541. 80

Délétion clonale et TCR transgénique



IF2010 BMC423 IF-IIIb

81

Figure 10-8
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

83

Sélection et TCR transgénique

Selection in SCID mice transgenic for H-2D^b/H-Y TCR

Phenotype	Positive selection		Negative selection	
	Transgenic females		Transgenic H-2 ^b	
	H-2 ^{b/d}	H-2 ^{d/d}	Males	Females
CD4 ⁻ 8 ⁻ TCR ⁻	+	++	+++	+
CD4 ⁺ 8 ⁺ TCR [±]	++	++	—	+++
CD4 ⁻ 8 ⁺ TCR ⁺⁺	+	—	—	+
CD4 ⁺ 8 ⁻ TCR ⁺⁺	—	—	—	—

IF2010 BMC423 IF-IIIb

84

Experimental procedure—fetal thymic organ culture (FTOC)




Figure 10-9a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2010 BMC423 IF-IIIb

85



Development of CD8⁺ CD4⁻ MHC I-restricted cells

Figure 10-9b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

IF2010 BMC423 IF-IIIb

86



IF2010 BMC423 IF-IIIb

87

Peptides agonistes, antagonistes (1)

Peptide ligand altéré (APL)

= peptide analogue d'un peptide immunogène

Agoniste → Conserve certaines fonctions d'activation


Antagoniste passif → Compétition pour le CMH

Antagoniste actif → induction d'anergie, modification de la cascade d'activation

IF2010 BMC423 IF-IIIb

88


Peptides agonistes, antagonistes (2)



IF2010 BMC423 IF-IIIb


D'après Sloan-Lancaster et Allen (1996) *Annu. Rev. Immunol.* 14:1-23

Peptides agonistes, antagonistes (3)



IF2010 BMC423 IF-IIIb


90



IF2010 BMC423 IF-IIIb

Godfrey and Zlotnik (1993) *Immunol. Today* 14:457. 92

Sélection CD8/CMHI & CD4/CMHII (1)



IF2010 BMC423 IF-IIIb

9:

Sélection CD8/CMHI & CD4/CMHII (2)




Figure 10-10 part 1
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

95

Sélection CD8/CMHI & CD4/CMHII (3)






Figure 10-10 part 2
Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company

IF2010 BMC423 IF-IIIb

94

Sélection CD8/CMHI & CD4/CMHII (4)




Current Opinion in Immunology*

IF2010 BMC423 IF-IIIb

Singer, A. (2002) *Curr.Opin.Immunol.* 14, 207-215

Sélection CD8/CMHI & CD4/CMHII (5)

Modèle cinétique d'engagement CD4/CD8



Un arrêt du signal
promeut la
différenciation en
lymphocyte T CD8SP


Current Opinion in Immunology

IF2010 BMC423 IF-IIIb

Singer, A. (2002) *Curr.Opin.Immunol.* 14, 207-215

Sélection CD8/CMHI & CD4/CMHII (6)

Modèle cinétique d'engagement CD4/CD8




Un signal persistant
promeut la
différenciation en
lymphocyte T CD4SP

Current Opinion in Immunology

IF2010 BMC423 IF-IIIb

Singer, A. (2002) *Curr.Opin.Immunol.* 14, 207-215

Sélection CD8/CMHI & CD4/CMHII (7)



IF2010 BMC423 IF-IIIb


Tyznik, Sun & Bevan (2004) *J. Exp. Med.* 199:559. 101

Conclusion

IF2010 BMC423 IF-IIIb

102

Sélections centrale et périphérique



IF2010 BMC423 IF-IIIb

103

Notions de répertoires (3)

- La diversité des récepteurs spécifiques de l'antigène du répertoire disponible de lymphocytes matures périphériques conditionne la capacité à répondre aux **antigènes du non-soi**.
- Cette diversité disponible est en fait façonnée, notamment pendant la différenciation lymphocytaire, par les **antigènes du soi**.

IF2010 BMC423 IF-IIIb

104

There is only one immune system! The view from immunopathology. A. M. Silverstein and N. R. Rose. *Semin. Immunol.* 12:173-178, 2000.

- The immune system does not 'decide' that a stimulus is deadly or harmless and respond accordingly.
- The world is not divided between the self and the not-self (foreign). The immune system does not 'know' the difference. Only obedience to the immunological rules defines what is tolerated and what is intolerable.
- SELF IS ONLY THAT COLLECTION OF POTENTIAL IMMUNOGENS THAT CANNOT STIMULATE A RESPONSE (or only a subliminal one) AT THAT TIME AND PLACE! This inability, which we name immunological tolerance [...] is the result of a multitude of central and peripheral down-regulatory mechanisms that have acted according to their own rules.
- Any 'foreign' epitope can become 'self' if administered appropriately, and any 'self' epitope can become 'foreign' and cause autoimmune disease, if tolerance is overcome with an adjuvant, by an intercurrent infection, by molecular mimicry, or by a variety of other means.
- Again, the immune system does not 'choose' immunoprotection or immunopathology in response to a challenge; both will occur in any event, and the fixed rules only determine the relative balance of the two.

IF2010 BMC423 IF-IIIb

105